Biogen executive plays down looming competition for its Alzheimer's drug
Adds executive comments in paragraphs 3-4, analysts' comments in paragraphs 9-11
By Sriparna Roy
June 12 (Reuters) -Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
Leqembi, co-developed by Biogen and its Japanese partner Eisai 4523.T, had won standard approval from the U.S. Food and Drug Administration last July. It sees a potential rival in Eli Lilly's LLY.N experimental Alzheimer's treatment donanemab.
"Competition or another option is always a good thing," said Biogen's North America head Alisha Alaimo.
"But more importantly, the market will develop faster with Lilly in play," Alaimo said, adding that she cannot speculate what will happen with donanemab's label.
Outside advisers to the FDA unanimously backed the use of donanemab for the treatment of early Alzheimer's disease on Monday, clearing the way for a final regulatory decision on the treatment.
While the U.S. health regulator is not obligated to follow the panel's recommendations, it usually does so.
Leqembi's launch has so far been lackluster, with bottlenecks due to its requirements such as additional diagnostic tests, twice-monthly infusions and regular brain scans, which have contributed to a slower adoption of the drug than markets were expecting.
Analysts expect donanemab to ultimately be approved. Some have said having two players on the Alzheimer's drug market would help with its growth.
Leerink Partners analyst David Risinger, however, said assuming the FDA approves donanemab, its commercial adoption is expected to be limited relative to leqembi because Lilly's treatment has more safety liabilities and is less convenient with intravenous administration.
According to HSBC analysts, the two candidates — Biogen and Lilly — could start shaping a potential $100 billion market for the Alzheimer's treatments.
"While it is expensive to enter the space, once in, competition should be limited," the brokerage said in a report on Wednesday.
Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
